Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + dapagliflozin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rosuvastatin + dapagliflozin is a combination of two small molecule drugs used primarily for their respective effects on lipid and glucose metabolism. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol biosynthesis, leading to reduced LDL-C and triglycerides, and increased HDL-C. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Preclinical studies suggest this combination may have synergistic cardioprotective effects, particularly in reducing myocardial ischemia/reperfusion injury via activation of the PI3K/Akt/mTOR signaling pathway[1][6]. Both agents are approved individually for cardiovascular risk reduction in patients with type 2 diabetes or dyslipidemia; however, the fixed-dose combination is not currently marketed as a single product.
- Brand names
- Crestor + Farxiga
- Other names
- RSV + DGZ
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on rosuvastatin + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + dapagliflozin.